No abstract

BackgroundA rheumatic disease may be a casual factor in the pathogenesis of a neoplastic disease, as in other cases, cancer may lead to the development of paraneoplastic rheumatic manifestations that may be the only initial symptoms1. Lazarus et al. demonstrated in its cohort study with 112 patients that of the 22% of patients who developed some neoplasm during the study, the most prevalent was lymphoma with 44%. according to the same study, patients with pss present a risk 37.5 times more than that of the general population. of generating lymphoma, with another risk 2.6 times of developing another type of cancer2.it was also shown that in patients with pss there is an incidence of 320 cases per 100 000 a year of presenting non-hodgkin’s lymphoma3. In our country there are no epidemiological studies to know the prevalence of cancer in patients with pss, so these numbers are difficult to estimateObjectivesDetermine the prevalence of cancer in patients with ss in the mexican population.MethodsCross-sectional, observational study was conducted in which 393 patients were included, of which 221 (52%) came from the national institute of medical sciences and nutrition ”salvador zubiran”, 92 (23.4%) from the university hospital ”José E González” and 80 (20.6%) of the juárez mexico hospital/ABC medical centre whom fulfilled the diagnosis of ssp according to the 2002/2012 criteria of the american college of rheumatology/european league against rheumatism. Bivariate anailsis was performed, normality was demonstrated using the K.S test, the student’s T test was used for the numerical variables and the chi2 test for the categorical ones, and no difference was found between the characteristics of patients with or without cancer.ResultsWe include 393 patients, the majority were women (n=377, 95.9%) with an average age of 56.4 (±13.60), of these 23 (5.85%) had some type of neoplasm regardless of their malignancy. the most prevalent was lymphoma with 9 cases (34.6%), followed by breast cancer with 5 (19.2%), 3 (11.5%) of basal cell cancer and 2 (7.7%) cases of cervical uterine cancerAbstract AB0583 – Table 1Demographic characteristics in Patients with Primary Sjögren Syndrome (n:393)Abstract AB0583 – Figure 1Neoplasia prevalence in primary sjögren syndrome in Mexican-Mextizo patientsConclusionsWe confirmed lymphoma as the most prevalent neoplasia in a cohort of non-Caucasian pSS patients. We observed the presence of non-hematologicalmalignancy 60.86% of our patients, whether it risk is increased in pSS population still needs to be addressed.References[1] Bellan M, Boggio E, Sola D, Gibbin A, Gualerzi A, Favretto S, … Sainaghi PP. Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Internal and Emergency Medicine2017;12(5):621–627.[2] Lazarus MN. Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology2006;45(8):1012–1015.[3] Nishishinya MB, Pereda CA, Muñoz-Fernández S, Pego-Reigosa JM, Rúa-Figueroa I, Andreu JL, … Santamaría EL. Identification of lymph...

BackgroundThe idiopathic inflammatory myopathies (IIM) are a heterogeneous group of subacute, chronic, or acute acquired diseases of skeletal muscle, they can be classified into the following clinical pathologic groups: dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM) which differ in clinical presentation, season of onset, genetics, and prognosis.(1 Furthermore, the seropositivity of antibodies in these diseases can help to predict the evolution of the disease, and influence therapeutic strategies.(,2 Anti-Mi-2 is a classic marker for DM and its associated with good response for steroid treatment and good prognosis. Anti-SRP is specific for PM and its associated with treatment-resistant myopathy, histologically characterised as necrotizing myopathy. Several new myositis specific antibodies (MSA), autoantibodies with strong clinical significance have been described in IIM manifestations.3 The literature about this topic is limited in Hispanic population. This study represents an effort for a better understanding of this group of diseases.ObjectivesTo determine the prevalence of myositis specific and myositis associated autoantibodies in a cohort of patients with idiopatic inflammatory myopathies, who were treated from January 2016 to January 2018 in a Rheumatology Service from a University (Hospital Jose E. Gonzalez) from UANL and a centre for arthritis at north of Mexico.MethodsCross-sectional, retrospective descriptive study cohort of 95 patients who attended the rheumatological clinic in the period from January 2016 to January 2018 who met Bohan and Peter’s classification criteria. The determination of antibodies was performed by the Inmunoblot technique with Euroinmmun kit. The following serotypes were included: OJ, Ro 52, Mi2 α, MDA-5, TIF 1 gama, PM/Scl 75, Mi 2ß, SRP, PL12, PL 7, PM/Scl 100, Ku, Jo1, EJ, cN1A, NXP2, SAE 1. Statistical analysis was performed with univariate, for the categorical variables, absolute frequencies and percentages were analysed and for the numerical means and standard deviation with the SPSS V22 (Armonk, NY: IBM Corp.)ResultsFrom a cohort of 95 patients, 68.42% were women and 31.75% were men. The average age was 47±15.42. A prevalence of seropositive antibodies were observed for Mi2 α of 29 (30.52%), 14 (14.73%) in Tif 1gamma and 12 (12.63%) has positive Mda 5. Abstract AB0813 – Table 1Positive Antibodies.*SD: Standard DeviationConclusionsThe systematic and standardised evaluation of the determination of antibodies in patients with inflammatory myopathies play an important role in the predictive evaluation. Knowledge of the prevalence and clinical scenarios in various cohorts increase the standardisation and prompt use of antibodies in the classification of inflammatory myopathiesReferences[1] Dalakas, M.C. (2015), Inflammatory muscle disease. N Engl J Med, Volumen 372, 1734–1747.[2] Selva-O’ Callaghan A, Redondo-Benito A, Trallero-Araguas E, Martinez-Gomez X, Palou E, Vilardell-Tarres M. Clinical significance of thyroid disease in patients with inflammato...

No abstract

No abstract